Categories Analysis, Health Care

Earnings Preview: Here’s what to expect from Johnson & Johnson’s Q2

Market watchers estimate that second-quarter earnings and revenue increased modestly year-over-year

Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) entered a new phase recently after spinning off its consumer business. The move is part of the efforts to rejuvenate the business that experienced a slowdown during the pandemic and faces legal challenges over the safety of certain consumer products. The company will be publishing its second-quarter results next week.


Recently, Johnson & Johnson’s board raised the dividend by 5.3%, marking the 61st consecutive hike. That translated into an increase in the forward dividend yield to a bigger-than-average 3%. The stock’s performance has not been very impressive so far this year, as it mostly traded below the 12-month average. However, JNJ looks poised to gather steam in the coming months and grow in double-digits through mid-2024.

The company has carved a niche for itself in the pharma and consumer care market, with a good track record of creating shareholder value. While the valuation looks a bit high, JNJ is a relatively safe stock for the long term. Moreover, the management’s growth strategy is focused on continued innovation and the company has a promising pipeline. Earlier this month, the Janssen subsidiary reported positive topline results from an advanced study evaluating the first and only oral interleukin-23 receptor antagonist peptide JNJ-2113 for the treatment of plaque psoriasis.

Kenvue Spin-off

The recent separation of the consumer division elicited great interest among stakeholders as it is expected to make both Johnson & Johnson and Kenvue more agile and efficient. The fact that the company is facing multiple lawsuits for alleged safety issues related to its talc-based personal care products adds to the significance of the split.

When the company reports second-quarter results on July 20 in the morning, the market will be looking for a modest increase in earnings and revenues. Adjusted profit is estimated to have increased to $2.62 per share from $2.59 per share last year. The consensus revenue estimate is $24.66 billion, up 2.7%.

Earnings Beat

Johnson & Johnson has generated stronger-than-expected quarterly earnings consistently for more than a decade, an achievement probably no other company could match. In the most recent quarter, which ended in March 2023, earnings remained unchanged at $2.68 per share, while sales grew by 6% to $24.7 billion and topped expectations. The core Pharmaceutical division expanded by 4%, while sales increased across all geographical segments except Asia & Africa.

Speaking to analysts after the first-quarter earnings release, Johnson & Johnson’s CFO Joseph Wolk said, “The results reflect the strength and versatility of Johnson & Johnson and our commitment to improving healthcare outcomes around the world. 2023 has many important catalysts that can drive meaningful near and long-term value for Johnson & Johnson shareholders. We remain focused on the successful separation of our Consumer Health business, Kenvue, which will position both companies to be more agile, focused, and competitive. We are also expecting a number of pipeline advancements that will provide increased confidence in our Pharmaceutical and MedTech businesses.”

JNJ opened Friday’s session slightly below $160 and traded higher throughout the day. In the past six months, the stock lost about 8%.

Most Popular

After mixed Q4, Darden Restaurants stays focused on profitable sales growth

Darden Restaurants, Inc. (NYSE: DRI), which owns popular restaurant brands Olive Garden and LongHorn Steakhouse, has reported stronger-than-expected fourth-quarter results, sending the stock higher soon after the announcement. Contributions from

What to expect when McCormick & Company (MKC) reports Q2 2024 earnings results

Shares of McCormick & Company, Incorporated (NYSE: MKC) stayed green on Friday. The stock has dropped 4% over the past one month. The spices and condiments maker is scheduled to report

CarMax (KMX) Q1 2025 Earnings: Key financials and quarterly highlights

CarMax, Inc. (NYSE: KMX) reported its first quarter 2025 earnings results today. Net sales and operating revenues decreased 7.5% year-over-year to $7.1 billion. Net earnings decreased 33% to $152.4 million,

Add Comment
Viewing Highlight